Neuroblastoma

Transplant advances and outcomes

Autologous hematopoietic cell transplantation (HCT) has been well established as a treatment option for patients with neuroblastoma. However, allogeneic HCT may provide decreased relapse and prolonged survival, but more research is needed to narrow immunological parameters to reduce disease recurrence in patients with advanced disease. [1, 2]

Recommended timing for transplant consultation

• INRGSS L2 at diagnosis
  • MYCN amplification
  • age >18 months with unfavorable histology and segmental chromosome aberration
• INRGSS stage M at diagnosis:
  • MYCN amplification
  • age >18 months at diagnosis
  • age 12–18 months with unfavorable histology, segmental chromosome aberrations, or diploid DNA content

References

1. Hale GA, Arora M, Ahn KW. Allogeneic hematopoietic cell transplantation for neuroblastoma: The CIBMTR experience. Bone Marrow Transplant. 2013; 48(8): 1056-1064. Access
2. Pinto NR, Applebaum MA, Volchenboum SL, et al.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma.  J Clin Oncol. 2015;33:3008-3017. Access